Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS

Yichen Lu, C. David Pauza, Xusheng Lu, David C. Montefiori, Chris J Miller

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

A new simian-human immunodeficiency virus (SHIV) stock (SHIV 89.6PD), derived from plasma of a rhesus macaque used for in vivo serial passage of virulence-attenuated SHIV 89.6, produces systemic infection after intravenous, intravaginal, or intrarectal inoculation of rhesus macaques. Infection with this virus results in high levels of viral antigen in plasma, a precipitous decline in CD4+ T-cell counts, and a disease syndrome that is characteristic of AIDS. Rapid progression to disease was associated with failure to seroconvert to viral antigens, whereas longer survival was associated with production of antiviral antibodies. In Intravenously inoculated animals, peak antigenemia occurred at 7 days postinjection (PI) and severe CD4+ depletion occurred at 14 days PI. In mucosally infected animals, peak antigenemia occurred at 14 days PI and severe CD4+ depletion was not evident until 21 days PI. The 1-week delay in both viral antigenemia and CD4+ T-cell decline in mucosally infected animals is consistent with the hypothesis that, following vaginal inoculation, virus dissemination proceeds in a stepwise manner from the mucosal surface to the draining lymph nodes and subsequently to the bloodstream. This animal model can be used to test the ability of HIV-1 envelope-based vaccines to prevent infection or disease after challenge by the three major routes of HIV transmission.

Original languageEnglish (US)
Pages (from-to)6-18
Number of pages13
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume19
Issue number1
StatePublished - Sep 1 1998

Fingerprint

Simian Immunodeficiency Virus
Macaca mulatta
Antibody Formation
Antiviral Agents
Acquired Immunodeficiency Syndrome
HIV
Viral Antigens
Serial Passage
T-Lymphocytes
Virus Diseases
CD4 Lymphocyte Count
Infection
Virulence
Disease Progression
HIV-1
Vaccines
Animal Models
Lymph Nodes
Viruses

Keywords

  • Animal model
  • Pathogenic SHIV
  • Rectal infection
  • Vaccine challenge stock
  • Vaginal infection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

@article{cca0036c00994494927bc200189a3af1,
title = "Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS",
abstract = "A new simian-human immunodeficiency virus (SHIV) stock (SHIV 89.6PD), derived from plasma of a rhesus macaque used for in vivo serial passage of virulence-attenuated SHIV 89.6, produces systemic infection after intravenous, intravaginal, or intrarectal inoculation of rhesus macaques. Infection with this virus results in high levels of viral antigen in plasma, a precipitous decline in CD4+ T-cell counts, and a disease syndrome that is characteristic of AIDS. Rapid progression to disease was associated with failure to seroconvert to viral antigens, whereas longer survival was associated with production of antiviral antibodies. In Intravenously inoculated animals, peak antigenemia occurred at 7 days postinjection (PI) and severe CD4+ depletion occurred at 14 days PI. In mucosally infected animals, peak antigenemia occurred at 14 days PI and severe CD4+ depletion was not evident until 21 days PI. The 1-week delay in both viral antigenemia and CD4+ T-cell decline in mucosally infected animals is consistent with the hypothesis that, following vaginal inoculation, virus dissemination proceeds in a stepwise manner from the mucosal surface to the draining lymph nodes and subsequently to the bloodstream. This animal model can be used to test the ability of HIV-1 envelope-based vaccines to prevent infection or disease after challenge by the three major routes of HIV transmission.",
keywords = "Animal model, Pathogenic SHIV, Rectal infection, Vaccine challenge stock, Vaginal infection",
author = "Yichen Lu and Pauza, {C. David} and Xusheng Lu and Montefiori, {David C.} and Miller, {Chris J}",
year = "1998",
month = "9",
day = "1",
language = "English (US)",
volume = "19",
pages = "6--18",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS

AU - Lu, Yichen

AU - Pauza, C. David

AU - Lu, Xusheng

AU - Montefiori, David C.

AU - Miller, Chris J

PY - 1998/9/1

Y1 - 1998/9/1

N2 - A new simian-human immunodeficiency virus (SHIV) stock (SHIV 89.6PD), derived from plasma of a rhesus macaque used for in vivo serial passage of virulence-attenuated SHIV 89.6, produces systemic infection after intravenous, intravaginal, or intrarectal inoculation of rhesus macaques. Infection with this virus results in high levels of viral antigen in plasma, a precipitous decline in CD4+ T-cell counts, and a disease syndrome that is characteristic of AIDS. Rapid progression to disease was associated with failure to seroconvert to viral antigens, whereas longer survival was associated with production of antiviral antibodies. In Intravenously inoculated animals, peak antigenemia occurred at 7 days postinjection (PI) and severe CD4+ depletion occurred at 14 days PI. In mucosally infected animals, peak antigenemia occurred at 14 days PI and severe CD4+ depletion was not evident until 21 days PI. The 1-week delay in both viral antigenemia and CD4+ T-cell decline in mucosally infected animals is consistent with the hypothesis that, following vaginal inoculation, virus dissemination proceeds in a stepwise manner from the mucosal surface to the draining lymph nodes and subsequently to the bloodstream. This animal model can be used to test the ability of HIV-1 envelope-based vaccines to prevent infection or disease after challenge by the three major routes of HIV transmission.

AB - A new simian-human immunodeficiency virus (SHIV) stock (SHIV 89.6PD), derived from plasma of a rhesus macaque used for in vivo serial passage of virulence-attenuated SHIV 89.6, produces systemic infection after intravenous, intravaginal, or intrarectal inoculation of rhesus macaques. Infection with this virus results in high levels of viral antigen in plasma, a precipitous decline in CD4+ T-cell counts, and a disease syndrome that is characteristic of AIDS. Rapid progression to disease was associated with failure to seroconvert to viral antigens, whereas longer survival was associated with production of antiviral antibodies. In Intravenously inoculated animals, peak antigenemia occurred at 7 days postinjection (PI) and severe CD4+ depletion occurred at 14 days PI. In mucosally infected animals, peak antigenemia occurred at 14 days PI and severe CD4+ depletion was not evident until 21 days PI. The 1-week delay in both viral antigenemia and CD4+ T-cell decline in mucosally infected animals is consistent with the hypothesis that, following vaginal inoculation, virus dissemination proceeds in a stepwise manner from the mucosal surface to the draining lymph nodes and subsequently to the bloodstream. This animal model can be used to test the ability of HIV-1 envelope-based vaccines to prevent infection or disease after challenge by the three major routes of HIV transmission.

KW - Animal model

KW - Pathogenic SHIV

KW - Rectal infection

KW - Vaccine challenge stock

KW - Vaginal infection

UR - http://www.scopus.com/inward/record.url?scp=0032169938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032169938&partnerID=8YFLogxK

M3 - Article

C2 - 9732063

AN - SCOPUS:0032169938

VL - 19

SP - 6

EP - 18

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 1

ER -